153 research outputs found
Clinical Implication of Targeting of Cancer Stem Cells
The existence of cancer stem cells (CSCs) is receiving increasing interest particularly due to its potential ability to enter clinical routine. Rapid advances in the CSC field have provided evidence for the development of more reliable anticancer therapies in the future. CSCs typically only constitute a small fraction of the total tumor burden; however, they harbor self-renewal capacity and appear to be relatively resistant to conventional therapies. Recent therapeutic approaches aim to eliminate or differentiate CSCs or to disrupt the niches in which they reside. Better understanding of the biological characteristics of CSCs as well as improved preclinical and clinical trials targeting CSCs may revolutionize the treatment of many cancers. Copyright (c) 2012 S. Karger AG, Base
A Minimum Column Density of 1 g cm^-2 for Massive Star Formation
Massive stars are very rare, but their extreme luminosities make them both
the only type of young star we can observe in distant galaxies and the dominant
energy sources in the universe today. They form rarely because efficient
radiative cooling keeps most star-forming gas clouds close to isothermal as
they collapse, and this favors fragmentation into stars <~1 Msun. Heating of a
cloud by accreting low-mass stars within it can prevent fragmentation and allow
formation of massive stars, but what properties a cloud must have to form
massive stars, and thus where massive stars form in a galaxy, has not yet been
determined. Here we show that only clouds with column densities >~ 1 g cm^-2
can avoid fragmentation and form massive stars. This threshold, and the
environmental variation of the stellar initial mass function (IMF) that it
implies, naturally explain the characteristic column densities of massive star
clusters and the difference between the radial profiles of Halpha and UV
emission in galactic disks. The existence of a threshold also implies that
there should be detectable variations in the IMF with environment within the
Galaxy and in the characteristic column densities of massive star clusters
between galaxies, and that star formation rates in some galactic environments
may have been systematically underestimated.Comment: Accepted for publication in Nature; Nature manuscript style; main
text: 14 pages, 3 figures; supplementary text: 8 pages, 1 figur
Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
In multiple myeloma, circulating “clonotypic” B cells, that express the immunoglobulin rearrangement of the malignant plasma cell clone, can be indirectly detected by PCR. Their role as potential “feeder” cells for the malignant plasma cell pool remains controversial. Here we established for the first time an approach that allows direct tracking of such clonotypic cells by labeling with patient-specific immunoglobulin ligands in 15 patients with myeloma. Fifty percent of patients showed evidence of clonotypic B cells in blood or bone marrow by PCR. Epitope-mimicking peptides from random libraries were selected on each patient's individual immunoglobulin and used as ligands to trace cells expressing the idiotypic immunoglobulin on their surface. We established a flow cytometry and immunofluorescence protocol to track clonotypic B cells and validated it in two independent monoclonal B cell systems. Using this method, we found clonotypic B cells in only one out of 15 myeloma patients. In view of the assay's validated sensitivity level of 10−3, this surprising data suggests that the abundance of such cells has been vastly overestimated in the past and that they apparently represent a very rare population in myeloma. Our novel tracing approach may open perspectives to isolate and analyze clonotypic B cells and determine their role in myeloma pathobiology
Modeling Evolutionary Dynamics of Epigenetic Mutations in Hierarchically Organized Tumors
The cancer stem cell (CSC) concept is a highly debated topic in cancer research.
While experimental evidence in favor of the cancer stem cell theory is
apparently abundant, the results are often criticized as being difficult to
interpret. An important reason for this is that most experimental data that
support this model rely on transplantation studies. In this study we use a novel
cellular Potts model to elucidate the dynamics of established malignancies that
are driven by a small subset of CSCs. Our results demonstrate that epigenetic
mutations that occur during mitosis display highly altered dynamics in
CSC-driven malignancies compared to a classical, non-hierarchical model of
growth. In particular, the heterogeneity observed in CSC-driven tumors is
considerably higher. We speculate that this feature could be used in combination
with epigenetic (methylation) sequencing studies of human malignancies to prove
or refute the CSC hypothesis in established tumors without the need for
transplantation. Moreover our tumor growth simulations indicate that CSC-driven
tumors display evolutionary features that can be considered beneficial during
tumor progression. Besides an increased heterogeneity they also exhibit
properties that allow the escape of clones from local fitness peaks. This leads
to more aggressive phenotypes in the long run and makes the neoplasm more
adaptable to stringent selective forces such as cancer treatment. Indeed when
therapy is applied the clone landscape of the regrown tumor is more aggressive
with respect to the primary tumor, whereas the classical model demonstrated
similar patterns before and after therapy. Understanding these often
counter-intuitive fundamental properties of (non-)hierarchically organized
malignancies is a crucial step in validating the CSC concept as well as
providing insight into the therapeutical consequences of this model
Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)
The aim of this study was to assess the effects of the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on attention in rats as measured using the 5-choice-serial-reaction-time task (5CSRTT) and to investigate whether methylphenidate has effects on DSP4-treated rats. Methylphenidate is a noradrenaline and dopamine reuptake inhibitor and commonly used in the pharmacological treatment of individuals with attention deficit/hyperactivity disorder (ADHD). Wistar rats were trained in the 5CSRTT and treated with one of three doses of DSP4 or saline. Following the DSP4 treatment rats were injected with three doses of methylphenidate or saline and again tested in the 5CSRTT. The treatment with DSP4 caused a significant decline of performance in the number of correct responses and a decrease in response accuracy. A reduction in activity could also be observed. Whether or not the cognitive impairments are due to attention deficits or changes in explorative behaviour or activity remains to be investigated. The treatment with methylphenidate had no beneficial effect on the rats’ performance regardless of the DSP4 treatment. In the group without DSP4 treatment, methylphenidate led to a reduction in response accuracy and bidirectional effects in regard to parameters related to attention. These findings support the role of noradrenaline in modulating attention and call for further investigations concerning the effects of methylphenidate on attentional processes in rats
Sexual dimorphism in cancer.
The incidence of many types of cancer arising in organs with non-reproductive functions is significantly higher in male populations than in female populations, with associated differences in survival. Occupational and/or behavioural factors are well-known underlying determinants. However, cellular and molecular differences between the two sexes are also likely to be important. In this Opinion article, we focus on the complex interplay that sex hormones and sex chromosomes can have in intrinsic control of cancer-initiating cell populations, the tumour microenvironment and systemic determinants of cancer development, such as the immune system and metabolism. A better appreciation of these differences between the two sexes could be of substantial value for cancer prevention as well as treatment
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs
Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth
Effect of the Aedes fluviatilis saliva on the development of Plasmodium gallinaceum infection in Gallus (gallus) domesticus
- …